Artificial intelligence specialist Scipher Medicine has signed an inflammatory bowel disease collaboration with Galapagos that exemplifies what Scipher is hoping to establish as its business model – repurposing the AI it uses to sift through mountains of clinical-genomic patient data for its diagnostics business to also identify novel targets that may lead to drug therapies for non-responding patients. [Editor's note: This article has been corrected to note that Scipher's patient data are not derived from clinical trials.]
Scipher Hopes IBD Alliance With Galapagos Is The First Of Many
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.